Avantra® Biosciences introduces the Rapid Assay Prototyping Service. Avantra’s new service allows researchers to accelerate their research efforts using custom designed biomarker assays developed on Avantra’s QPDx™ BioChip platform. The QPDx platform offers users rapid quantitative multiplex protein assays using catalog or custom reagents.

Avantra’s service offering provides researchers and clinicians with rapidly prototyped disease-specific biomarker assays. To provide this service, Avantra leverages pre-validated antibody pairs that can be further optimized for specific research needs. In addition, Avantra can design QPDx assays that use a client’s own immunoassay reagents. Avantra’s assays can be used for screening drug targets, pathway analysis, and disease state biomarker profiling.

The Avantra Biomarker System is currently being evaluated and used by a variety of health care institutions and research organizations for both research and potential point-of-care applications. This service greatly increases the versatility of the Avantra system providing researchers and clinician’s maximum operational efficiencies and reduced costs.